

International Working Group (IWG) Response Criteria for MDS

IWG Criteria for Response		
Category	Original (sustained ≥ 8 weeks)	Modified (sustained ≥ 4 weeks)
CR: Marrow	< 5% blasts; no dysplasia; normal maturation of all cell lines	≤ 5% blasts; normal maturation of all cells lines
CR: Peripheral blood	Hgb ≥ 11 g/dL; ANC ≥ 1500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia	Hgb ≥ 11 g/dL; ANC ≥ 1000/mL; platelets ≥ 100,000/mL; 0% blasts; hematologic improvement responses noted in addition to marrow CR
PR	Same as CR, except blasts ↓ by ≥ 50% or lower FAB	Same as CR, except blasts ↓ by ≥ 50%, still greater than 5% in marrow
IWG Criteria for Hematologic Improvement		
Category	Pretreatment	Modified IWG Response Criteria* (≥ 8 weeks)
Erythroid (HI-E)	Hgb < 11 g/dL	Hgb ↑ of ≥ 1.5 g/dL
		↓ of ≥ 4 RBC transfusions/8 weeks versus pretreatment requirement in previous 8 weeks; only RBC transfusions given for a pretreatment Hgb of ≤ 9.0 g/dL count
Platelet (HI-P)	< 100,000/mL	↑ of ≥ 30,000/mL (starting with > 20,000/mL)
		↑ from < 20,000/mL to > 20,000/mL by ≥ 100%
Neutrophil (HI-N)	< 1000/mL	↑ of ≥ 100% and > 500/μL
Progression/Relapse after hematologic improvement		≥ 1 of the following: ≥ 50% decrement from maximum response levels in granulocytes or platelets; ↓ in Hgb by ≥ 1.5 g/dL; transfusion dependence

Cheson et al. *Blood*. 2000;96:3671-3674.

Cheson et al. *Blood*. 2006;108:419-425.